A rationale for the use of beta-blockers as standard treatment for heart failure (Q33846412)

29 July 2017

1 reference

title

A rationale for the use of beta-blockers as standard treatment for heart failure (English)

1 reference

29 July 2017

M Metra

1 reference

29 July 2017

S Nodari

1 reference

29 July 2017

A D'Aloia

1 reference

29 July 2017

L Bontempi

1 reference

29 July 2017

E Boldi

1 reference

29 July 2017

L D Cas

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 March 2000

1 reference

29 July 2017

published in

American Heart Journal

1 reference

29 July 2017

volume

139

1 reference

29 July 2017

1 reference

29 July 2017

page(s)

511-521

1 reference

The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Why does the myocardium fail? Insights from basic science

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Mechanism of action of beta-blocking agents in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Role of beta-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Molecular and cellular mechanisms of myocardial failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Double-Blind, Placebo-Controlled Study of the Long-term Efficacy of Carvedilol in Patients With Severe Chronic Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Cardiac adrenergic receptor effects of carvedilol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Beta2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta2-adrenergic stimulation in animals susceptible to sudden death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

An alpha-1-adrenergic receptor subtype is responsible for delayed afterdepolarizations and triggered activity during simulated ischemia and reperfusion of isolated canine Purkinje fibers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Beta blockade during and after myocardial infarction: an overview of the randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990096-6

10.1016/S0002-8703(00)90096-6

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference